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The actin crosslinking domain (ACD), a product of pathogenic Gram-negative bacteria 
Vibrio cholera, Vibrio vulnificus and Aeromonas hydrophila, is a potent, actin-specific toxin. 
Once in the cytoplasm of host cells, ACD catalyzes the intermolecular, amide bond formation 
between the actin residues glutamic acid-270 and lysine-50 in two different actin monomers. 
This crosslinking leads to the formation of non-polymerizable actin oligomers and eventual cell 
rounding. Recently, our laboratory found that actin oligomers potently inhibit formins, a family 
of actin binding proteins that regulates many actin-dependent processes. This potency of actin 
oligomers is achieved by binding with high affinity to tandemly organized G-actin-binding 
domains in formins, an attribute enabled by binding to multiple sites on the formins. Similarly, it 
is possible that actin oligomers may affect other actin regulatory proteins that have several actin-
binding domains organized in close proximity. Ena/VASP is such an actin regulatory protein, 
which increases the rate of actin polymerization approximately two to three fold. Previously, 
Ena/VASP had not been identified as a target of bacterial toxins. 
To study the effects of actin oligomers on Ena-controlled actin polymerization, we 
employed pyrene polymerization assays. A potent, dose-dependent inhibition of Ena by 
oligomers was observed both in the presence and absence of profilin, a major regulator of 
polymerization of actin monomers. We also determined that profilin does not play a significant 
role in the inhibition mechanism. These results suggest that the mechanism of filament growth 
inhibition is similar to that of a capping protein where the inhibition occurs once Ena is already 
associated with the actin filament. The observation of single filament growth in the presence of 
Ena and oligomers will help to confirm this mechanism. Further understanding of the role of 
ACD-crosslinked actin oligomers will allow us to create tools to study and control Ena/VASP-
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1.1 Bacterial toxins and their cellular effects 
Bacterial toxins are the deadliest compounds on Earth; single copies of some toxins are 
sufficient to kill an entire host. In general, toxins are able to be so efficient by targeting proteins 
that are essential for survival of the host (e.g. inhibition of protein synthesis by the diphtheria 
toxin (1)) or by acting on signal transduction cascades (e.g. modification of the G-Coupled 
Protein Receptor signaling cascade (2)). Conversely, actin, a major component of a host’s 
cytoskeleton, is often a target of bacterial toxins through direct modification (3). Because actin is 
one of the most abundant proteins in the cell, with concentrations exceeding 100 µM (4), it was 
unclear until recently how actin specific toxins could achieve such high efficiency.   
1.2 Cellular roles of actin 
 Actin is a 42 kDa, ubiquitously expressed protein found in all eukaryotic cells. In the cell, 
actin exists in equilibrium between monomeric actin (G-actin) and filamentous actin (F-actin); 
under appropriate conditions, G-actin can polymerize to form F-actin and F-actin can 
depolymerize into G-actin. Actin serves numerous roles within the cell: it allows cells to alter 
their shape, divide, exo- and endocytose, and be motile (6). Accordingly, actin serves significant 
roles in host immunity. The actin cytoskeleton allows the immune system to carry out many of 
its necessary functions such as migration, phagocytosis, B and T cell activation, secretion, and 
cell-cell interactions (7). To carry out these roles, actin functions in association with many other 
proteins that regulate the dynamic equilibrium to increase or decrease the rate of polymerization 
and elongation and assist in forming higher-order actin assemblies (e.g., branched networks and 




1.3 Actin-specific toxins 
 Since actin plays many important roles in host immunity, it is not surprising that 
pathogens have developed a way to compromise the structure and function of the actin 
cytoskeleton and/or utilize the actin cytoskeleton for their advantage. One way that bacteria can 
manipulate the actin cytoskeleton is through the production of toxins. Bacterial toxins effecting 
actin typically fall in one of three groups: those that nucleate actin and increase the F-actin pool 
while decreasing the G-actin pool, those that sequester G-actin and increase the G-actin pool 
while decreasing the F-actin pool, and those that activate or inactive Rho GTPases. Activation of 
Rho GTPases increases the polymerization of actin. Through the interaction between the host 
Arp2/3 complex and the ActA protein on Listeria monocytogenes, Act A causes the nucleation of 
G-actin and a shift in the equilibrium towards F-actin (8). The Clostridium botulinum C2 toxin, 
Salmonella enterica SpvB toxin, and Clostridium perfringens iota toxin cause ADP-ribosylation 
of actin at arginine-177, which inhibits its polymerization (3). The bacterial toxins from 
Clostridium difficile, Clostridium sordellii, and Clostridium novyi inactivate Rho family proteins 
through glycosylation, while the necrotic factor from Escherichia coli activates Rho by 
deamidation (2).  
1.4 ACD catalyzes formation of covalent actin oligomers 
 The actin crosslinking domain (ACD) does not modify actin like all other known 
bacterial toxins. ACD depletes the pools of both G- and F-actin, unlike the toxins mentioned 
previously. ACD is an actin-specific toxin found within the larger group of MARTX and VgrG1 
toxins found in Gram-negative bacteria from some Vibrio and Aeromonas species (9). Once 
delivered to the cytoplasm of the host cell, ACD catalyzes the intermolecular amide bond 
formation between the actin residues glutamic acid-270 (E270) and lysine-50 (K50), leading to 
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the formation of various size actin oligomers (10). K50 is located on subdomain 2 of an actin 
monomer while E270 is located on subdomain 3. When the amide bond forms between the 
residues, it causes a twist in subdomain 2 that disrupts the normal inter-subunit interface between 
actin monomers during the formation of an actin filament, resulting in its inability to polymerize 
(Figure 1) (10). ACD converts monomeric actin into cross-linked actin oligomers, decreasing 
both the monomeric and filamentous actin pools (11) and leading to the loss of critical functions 
such as motility, contractility and rigidity (12). In vivo, the addition of oligomers results in the 
disassembly of actin stress fibers and cell rounding (13). 
1.5 Oligomer toxicity and actin-regulatory proteins 
 Until recently, the accepted hypothesis of ACD toxicity was the bulk accumulation of 
ACD–crosslinked actin oligomers (14). Given the high concentration of actin within the cell 
(>100 µM) and the rate of single molecule ACD-mediated acting crosslinking (15), it was 
previously determined that it would take over six months for a single ACD molecule per cell to 
crosslink half the actin cytoskeleton (9). The vast amount of actin within the cell would seem to 
make ACD a very inefficient toxin. Yet, our lab recently found that relatively low amounts of 
intracellular cross-linked oligomers (2-6%) caused a dramatic change in cell morphology, 
indicating that the oligomers likely play an active role in toxicity (9). The oligomers possess a 
unique and toxic combination of properties found in neither F- nor G-actin: unlike F-actin, they 
can bind G-actin binding proteins (e.g. profilin and thymosin-β4), but unlike G-actin, the 
oligomers contain multiple binding sites for such proteins. It was hypothesized that these unique 
characteristics would allow the oligomer to bind to tandem-organized actin binding domains of 
key actin assembly factors such as formins (9). Formins are homo-dimeric proteins characterized 
by their formin-homology 1 and 2 domains (FH1, FH2). The FH1 domains are made up of 
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multiple poly-proline rich regions in tandem, each capable of binding actin monomers in 
complex with the G-actin binding protein profilin. The FH2 domain forms a homodimer that 
stays processively attached to the barbed end of a growing actin filament. Binding of actin-
profilin complexes to the FH1 domains increase a local concentration of polymerization-
competent actin monomers and feed the FH2 domain with G-actin to increase the rate of filament 
elongation by 5-10 fold (16). When actin oligomers were introduced into in vitro actin 
polymerization assays, they exhibited a dose-dependent inhibition on formin-mediated actin 
elongation (9).  
Formins are not unique in having multiple actin binding domains. In fact, a majority of 
proteins that regulate the actin cytoskeleton have several actin-binding domains in proximity 
(either in tandem or due to oligomerization (17)). Therefore, it is likely that more than just the 
formin family of proteins that are targeted by the actin oligomers. One candidate is the 
Ena/VASP family of proteins, a filament assembly factor. 
1.6 Ena/VASP protein family 
 The Ena/VASP family of proteins are found across a wide variety of eukaryotes and 
share the same structural domains (18). For example, Dictyostelium discoideum expresses 
DdVASP, Drosophila expresses Ena (Enabled), and mammals express EVL (Ena/VASP-like), 
Mena (mammalian Ena), and VASP (vasodilator-stimulated phosphoprotein) (18). In vivo, 
Ena/VASP proteins gather and promote elongation of lamellipodial actin-barbed ends as well as 
antagonize the inhibition of polymerization by capping protein. As an active tetramer, Ena/VASP 
can stay processively attached to the growing actin filament (19). Mice and Drosophila studies 
indicate that Mena and Ena function in the axonal architecture of both the central and peripheral 
nervous system, respectively (18). VASP is involved in numerous processes including platelet 
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aggregation, as VASP deficient mice exhibit defects in the actin-dependent process of platelet 
aggregation (12).  
While different members of the Ena/VASP family slightly vary in their structure and 
amino acid composition, they all form tetramers and therefore contain several G-actin binding 
domains in close proximity. This allowed us to focus on Ena alone as a representative member of 
the family that can be expressed in bacteria. Therefore, conclusions from the work presented here 
can be extended into the human model (20). Like all other members of the family, Ena contains 
an Ena/VASP homology domain 1 (EVH1), a polyproline-rich region and EVH2 domain (Figure 
2). In its active form, Ena exists as a tetramer, which is largely facilitated by its coiled-coil 
domain in EVH2 (18). This tetramerization allows Ena to increase the elongation rate of actin 
between two to three-fold (19). Additionally, there is a linker between the EVH1 and 
polyproline-rich region of unknown function. Deletion of this linker (Ena(ΔL)) has also been 
shown not to effect the elongation rate of Ena-controlled actin filaments in vitro. It is likely this 
linker region is important for localization and appropriate function in vivo. Also, because 
Ena(ΔL) has a higher protein yield upon expression in E. coli and is more active after long-term 
storage at -80 °C as compared to the full length protein (19), it was utilized in all experiments 
completed for this thesis. 
1.7 Functional roles of the EVH1 domain and polyproline-rich regions 
 The first 115 residues of the Ena protein is the EVH1 domain. These residues play 
important roles in forming links to host proteins that contribute/regulate various signal 
transduction pathways. EVH1 is a non-catalytic protein interaction domain that specifically binds 
to target proline-rich (FPPPP-containing) sequences. These sequences are found in mammalian 
proteins including the focal adhesion proteins zyxin and vinculin as well is in the ActA protein 
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for the pathogen Listeria monocytogenes. In general, the binding to the FPPPP sequences has a 
low affinity and high specificity in order to carry out successful signaling cascades (21). 
 Another highly conserved region in the Ena/VASP family is the polyproline-rich region. 
Through analysis of the distribution of hydrophobic amino acid clusters, three distinct groups of 
proline residues were observed in all members of the Ena/VASP family. It is hypothesized by 
Ferron et al. that each of these groups has their own specific role in Ena function to bind profilin-
actin complexes, the major pool of polymerization competent actin within eukaryotic cells (22). 
The first polyproline rich region is termed the regulatory region and consists of a mixture of 
proline and hydrophobic amino acids. This mixture is a feature of SH3 (SRC Homology 3) and 
WW-binding sequences that are located on a number of signaling proteins. This site does not 
correspond to a profilin-binding sequence and is likely involved in regulation by SH3 proteins. 
The next region is termed the recruiting site as it contains three repeats of the specific profilin-
binding sequence GPPPPP and can subsequently bind multiple profilin-actin complexes. The 
final region is the loading site, which is highly conserved among all members of the Ena/VASP 
family (22). This site is located between the recruiting site and EVH2. It is flanked by short 
flexible glycine linkers and participates in delivering profilin-actin from the polyproline-rich 
region to the EVH2. Tentatively, profilin-actin can move from region to region toward the EVH2 
domain due to increasing affinity to each subsequent site (22).     
1.8 Function of the EVH2 domain 
 The C-terminal portion of the protein is the highly conserved EVH2 domain, made up of 
the G-actin binding domain (GBD), the F-actin binding domain (FBD) and the coiled-coil motif. 
The KLKK sequence of the G-actin binding domain resembles a motif in thymosin-β4, an actin 
monomer-binding protein (23). This binding site contacts the gelsolin- and profilin-binding sites 
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on the barbed end of actin monomers without blocking the DNAseI binding on subdomain 2 of 
the monomer (24). The FBD can bind and bundle F-actin (18). Coordination between the G-actin 
binding domains and F-actin-binding domains in the tetramer allows Ena to stay processively 
attached to the filament. The FBD binds to the sides of the filament, tethering the tetramer near 
the barbed end, and GBD binds to G-actin or, F-actin with lower affinity (Figure 11), to deliver 
actin monomers to the filament. Before one Ena peptide dissociates from the filament, any of the 
other peptides in the tetramer can bind to adjacent actin protomers and add a monomer, allowing 
for the processivity of the protein (19). 
1.9 Thesis overview 
 There were three primary goals for the work completed in this thesis. The first was to 
express and purify the active Ena(ΔL) construct. After this was completed, the next focus was to 
determine if ACD-crosslinked actin oligomers would inhibit Ena(ΔL)-mediated actin 
polymerization. This was entirely assessed through pyrene-actin polymerization assays. Since 
there is an inhibitory effect, the final goal was to determine how the oligomers are gaining their 
inhibitory effect. By changing the order of addition of actin oligomers, we gained an insight into 
the mechanism of oligomer inhibition. This goal still needs further experimentation looking at 
oligomer inhibition at a single filament level to confirm our model. 
 In the following chapters, I will explain the implication of my results and discuss some of 
my project’s challenges. Subsequently, I will propose a mechanism, future directions, and 
discuss the potential significance of this project on the importance of the study of ACD-
crosslinked actin oligomers. Finally, I will describe detailed methodology for Ena(ΔL) 
expression and purification, the formation of ACD-crosslinked actin oligomers, and the use of 




2.1 Ena expression and characterization 
 Active Ena(ΔL) was successfully expressed using E. coli  Codon Plus® cells and purified 
as described in “Methods”. Codon Plus® E. coli were selected since they are engineered to 
contain extra copies of genes that encode rare tRNAs in E. coli that are more abundant in 
sophisticated organisms, such as Drosophila. Purification was assessed using SDS-PAGE and 
was determined to be sufficiently pure without further purification steps necessary (Figure 3). 
The N-terminal maltose binding protein and C-terminal His tags were not cleaved from the 
protein as they were previously shown not to effect Ena(ΔL) activity (19). To assess the activity 
of the purified protein, we utilized pyrene actin polymerization assays to monitor polymerization 
of actin alone or in the presence of Ena(ΔL) (Figure 4). Ena(ΔL) increased the polymerization 
rate compared to actin alone (Table 1). In comparing the approximate elongation rate at ~50% of 
max polymerization (Figure 4A, Table 1), enhancement of polymerization plateaued at 
approximately 20 nM of Ena(ΔL), about a two-fold increase in the filament elongation rate 






without PFN1 (µM/s) 
(Figure 4A): 
Relative increase 
in elongation rate 
without PFN1: 





rate with PFN1: 
0 0.00091 1.0 0.00075 1.0 
10 0.00158 1.7 0.00106 1.4 
20 0.00173 1.9 0.00165 2.2 
40 0.00189 2.1 0.00166 2.2 
Table 1: Elongation rate analysis of polymerization traces in Figures 4A and 4B. 
 
Another way to look at the elongation rate increase by Ena(ΔL) is to compare the time it 
takes for each trace to reach half of its maximum polymerization at each concentration of 
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Ena(ΔL). The time to half maximum includes a waiting time that depends on the number of seed 
filaments that are nucleating spontaneously from monomers. Since Ena(ΔL) is not an actin 
nucleator (25), this should be the same at all concentrations of Ena(ΔL) and the actin control. In 
agreement with previous data (19), this data, shown in Table 2, also indicates that Ena(ΔL) 
increased the polymerization rate as compared to actin alone. Even though the results obtained 
by the two methods are overall very similar, in the latter case the rate enhancement of 
polymerization slightly increased between 20 and 40 nM of Ena(ΔL) suggesting either weak 
nucleation activity of Ena, or some other details in the activity of Ena that we do not fully 
understand. This further suggests that comparing time to half maximum polymerization is a more 





Time to half max 
polymerization 
without PFN1 (s) 
(Figure 4A): 
Relative times faster 
in reaching half max 
polymerization 
without PFN1: 
Time to half max 
polymerization 
with PFN1 (s)  
(Figure 4B): 
Relative times faster 
in reaching half max 
polymerization with 
PFN1: 
0 1808.6 1.0 4358.6 1.0 
10 1223.5 1.5 2723.6 1.6 
20 938.5 1.9 2363.5 1.8 
40 788.5 2.3 2093.5 2.1 
Table 2: Time to half maximum polymerization for the polymerization traces in Figures 4A and 
4B. 
 
Additionally, we tested activity in the presence of human profilin-1 (PFN1), and found 
that Ena(ΔL) was still able to increase the bulk rate of actin polymerization (Table 1,2). 
Similarly, enhancement of elongation plateaued at 20 nM of Ena(ΔL) for the data in Table 1, 
however, when looking at the time to half maximum polymerization (Table 2), the rate 
enhancement of polymerization again increased between 20 and 40 nM of Ena(ΔL). Both 
analyses of rate agreed on a two-fold increase compared to non-Ena(ΔL) controlled filaments. 
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Because Ena(ΔL) does not nucleate filaments at physiological salt concentrations (25), the 
addition of PFN1 did not significantly enhance the activity of Ena (Figure 4) in contrast to 
formins where profilin-actin complexes accelerated elongation by as much as 10-fold (9). This 
can be observed in the similar elongation rates at the same Ena(ΔL) concentrations in both the 
absence and presence of PFN1. In both the absence and presence of PFN1, the rate enhancement 
plateaued at approximately 20 nM of Ena(ΔL). Therefore, all subsequent assays utilized 20 nM 
of Ena(ΔL) to test the effects of actin oligomers. 
2.2 Actin oligomers inhibit Ena-controlled filament elongation in a dose dependent manner 
 It has been previously shown that actin oligomers have only a marginal effect on 
spontaneous actin polymerization in the absence and presence of PFN1 (9). When ACD-
crosslinked oligomers were mixed with Ena(ΔL) and actin, there was a potent decrease in the 
polymerization rate as the concentration of oligomers increased (Figure 5). To determine the 
median inhibitory concentration (IC50) of the oligomers, we determined the tangent slope of each 
curve at 50% (linear intervals of polymerization curves at 40-60% were assessed) in 
polymerization assays. Fitting the inhibition to an isotherm binding equation yielded an IC50 of 
3.70 ± 0.95 nM (Figure 6), suggesting that the oligomers are nearly as efficient in inhibition of 
Ena as in that of mDia1, a formin that was previously shown to be potently inhibited by the 
oligomers (9). High concentrations of the oligomers (> 100 nM) caused a mild reversal in 
inhibition. A likely interpretation of this effect is weakening of the filaments upon incorporation 
of a small fraction of the oligomers. Such weakening can result in filament severing leading to 
the generation of additional filament ends capable to participate in elongation and thus to 




2.3 Profilin does not play a major role in the oligomer inhibitory mechanism 
In cells, most of the G-actin pool is bound to profilin to inhibit spontaneous nucleation 
and regulate actin interaction with numerous filament assembly factors (6). In the presence of 
profilin, the addition of the oligomers showed a potent decrease in the bulk polymerization rate 
(Figure 7), of similar efficiency to that observed in the absence of profilin. An IC50 value of 3.21 
± 0.53 nM (Figure 6) was obtained, indicating that profilin does not play a role in the oligomers 
inhibition mechanism. There was not the reversal in potency of inhibition at high concentration 
of the oligomers as observed without profilin (Figure 7). This is because profilin inhibits 
incorporation of the oligomers into growing filaments (9).  
2.4 Oligomers inhibit Ena that is already associated with the growing filament 
 
 To gain insight into how the oligomers were achieving their inhibitory effect, the 
oligomers were added to Ena-controlled actin filaments. To generate Ena(ΔL)-controlled 
filaments, actin was polymerized in the presence of Ena(ΔL) and at approximately 15% of 
maximum polymerization, different concentrations of oligomers were added. A dose-dependent 
inhibition was observed as in the previous assays where oligomers were added before 
polymerization (Figure 8). If inhibition was only occurring by oligomer binding to Ena(ΔL) prior 
to association with the filament, the polymerization curves at all concentrations of oligomers 
would be unaffected. However, our results indicate that the oligomers are capable of bind to 
Ena(ΔL) that is associated with elongating filaments. Fitting the inhibition to the isotherm 
binding equations resulted in an IC50 of 5.80 ± 0.69 nM (Figure 9).  
 The role of profilin in the inhibition mechanism was also assessed though the addition of 
oligomers to Ena controlled filaments in the presence of PFN1. Similarly, there was a dose 
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dependent inhibition of Ena(ΔL)-mediated polymerization (Figure 10). With an IC50 value of 





 Many proteins play an active role in controlling actin dynamics. When these accessory 
proteins are inhibited or do not function normally, cellular processes can be greatly impacted. 
ACD is a bacterial toxin that works by producing toxic actin oligomers to inhibit these accessory 
proteins. Our goal is to understand which actin-binding proteins are affected by the oligomers, 
and apply this knowledge to develop novel tools for studying the actin cytoskeleton. Our results 
are the first example of Ena serving as a target for bacterial toxins.  
 Actin oligomers in the presence or absence of profilin have a dose-dependent inhibition 
of Ena. This inhibition is likely to be accountable, at least in part, for the observed cell rounding 
in cells treated with ACD. The mechanism by which the oligomers gain their inhibitory power is 
only partially understood (Figure 11). Ena, as an active tetramer, has multiple G-actin binding, F-
actin binding and poly-proline rich domains in close proximity (Figure 11, 13). The four F-actin 
binding domains allow for a walking action of the protein to stay processively attached to the 
barbed end of the growing actin filament (19). We propose that the four proximal G-actin 
binding domains provide a platform for multivalent, high affinity binding of the oligomers, 
which potently prevents further polymerization. Since the surface on actin that interacts with the 
G-actin binding domain of Ena is not altered by the ACD crosslink, the oligomers should be 
capable of binding to this domain. However, the crosslink induces a change in the monomer 
orientation that inhibits the formation of appropriate contacts within the growing filament; thus 
elongation stalls and Ena is converted into a filament capping protein. 
 Interestingly, the addition of profilin does not seem to have a major effect on the affinity 
of oligomers to Ena. The efficiency of inhibition is similar in polymerization assays where the 
oligomers were pre-mixed with Ena prior to the initiation of polymerization (and therefore had a 
chance to inhibit Ena in solution) or added after initiation of polymerization (when Ena is bound 
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to the filament barbed ends). This suggests that the active, filament-bound form of Ena is a target 
of the oligomers. There is a slightly stronger affinity for oligomers to Ena in the presence of 
PFN1 in seeded assays, possibly indicating that profilin helps to recruit oligomers through the 
interaction with the poly-proline rich domain in Ena, similar to what was found for formins (9). 
However, this recruitment plays only a minor role.  
While homologous to VASP, Ena is a Drosophila protein. In our assays, we used the 
human homolog of profilin, PFN1, rather than Drosophila profilin Chickadee. In an alignment 
allowing for gaps in the proteins, there is a 25% identity and 50% similarity between Chickadee 
and human profilin (26). It is not known if PFN1 is capable of binding to Ena, and therefore may 
explain our observation of profilin playing only a small role. Based on the similarity percentage, 
however, it is likely there will not be a difference when using Chickadee. Future experiments 
should still be done with Chickadee to confirm the results. 
 Our results indicate that the oligomers bind to and inhibit Ena after Ena associates with 
an actin filament. We confirmed that filaments previously elongating by Ena are potently 
inhibited by the addition of the oligomers. This can be confirmed using TIRF microscopy and 
looking at single actin filament growth controlled by Ena. It is also possible that the oligomers 
can bind only to free Ena in solution, however if this were the case, the addition of oligomers to 
the Ena-controlled polymerizing filaments should have resulted in no effect on the 
polymerization. Ena bound to oligomers can associate with the filament based on our 
spontaneous polymerization results.  
While future research is necessary in order to completely understand how the oligomers 
inhibit the polymerization rate enhancement of Ena-associated filament growth, a few important 
results have arisen from the work completed for this thesis. We learned that Ena(ΔL) is an 
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indirect target (through the produced oligomeric actin species) for bacterial toxins, specifically 
ACD in this case. Given that the inhibition of Ena by the oligomers is largely profilin-
independent, this indicates that the effect is mediated via oligomers binding to the WH2-domain 
of Ena. Therefore, this study is the first example that the ACD-crosslinked oligomers can target 
WH2-domain actin binding proteins (e.g. the GBD of Ena). These results strongly suggest that 
many other actin regulatory proteins containing tandem WH2-actin binding domains (i.e. Spire, 
Cobl, nucleation promoting factors assisting the activation of the Arp2/3 complex, etc.) are likely 
to be affected by actin oligomers. Finally, since we have found that ACD-crosslinked actin 
oligomers have a high affinity for Ena(ΔL), we can now utilize them to further study and control 














4. Materials and Methods 
 
4.1 Protein purification 
  
4.1.1 Actin 
Actin was prepared from acetone powder of rabbit skeletal muscle (Pel-Freeze 
Biologicals) as previously described (27), gel filtered, stored on ice in G-buffer (5mM Tris-HCl, 
pH 8.0, 0.2 mM CaCl2, 0.2 mM ATP, and 5 mM β-mercaptoethanol (βME)), and used within 
two weeks. 
4.1.2 ACD 
Thermo-labile ACD from Aeromonas hydrophila (ACDAh) was utilized as it can be 
inactivated under mild heating conditions that do not denature the oligomers themselves. The 
enzyme was expressed and purified as previously described (28). 
4.1.3 Ena(ΔL) 
 
 Ena(∆L), a construct containing EVH1, poly proline region, EVH2 and a coiled-coil 
domains (residues 1-112 and 297-684) in a pET21a-MBP(TEV) vector with N-terminal maltose 
binding protein (MBP) and C-terminal 6xHis tags, was a gift from Dr. David Kovar (University 
of Chicago). This construct was expressed in E. coli BL21 CodonPlus® competent cells in a rich 
bacterial cell growth medium (1.25% tryptone, 2.5% yeast extract, 1 mM proline, 125 mM NaCl, 
0.4% glycerol, and 50 mM Tris-HCl, pH 8.2). Expression was induced by the addition of 1 mM 
IPTG. Cells were incubated overnight at 16 °C before centrifugation. Cell pellets were 
resuspended in extraction buffer (50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 10% glycerol, 10 mM 
imidazole, 0.02 mg/mL LP, 0.02 mg/mL Trypsin inhibitor, 4 mM benzamidine, and 1 mM 
PMSF). Cells were lysed via sonication, and following clarification by centrifugation, the lysate 
was incubated with Talon® cobalt metal affinity resin (Clontech), washed extensively with lysis 
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buffer, and eluted with buffer containing 50 mM NaH2PO4, pH 8.0, 0.5 M NaCl, 10% glycerol, 
0.1 mM PMSF, and 250 mM imidazole. Samples containing Ena(ΔL), as detected by SDS-
PAGE, were dialyzed against storage buffer (20 mM HEPES, pH 7.4, 200 mM KCl, 0.01% 
NaN3, and 1 mM DTT). Ena(ΔL) was flash-frozen in liquid nitrogen and stored at -80 °C. The 
concentration of Ena(ΔL) was determined by comparing protein bands of various dilutions of 
Ena(ΔL) to protein bands of known actin concentration on a 7.5% SDS-PAGE gel.  
4.1.4 Human profilin 1 (PFN1) 
 PFN1 was expressed in E. coli BL21 Codon Plus® competent cells in a rich bacterial 
growth medium and was purified on poly-L-proline sepharose resin as previously described (29). 
Purified profilin was dialyzed against three storage buffer changes (2 mM Tris-HCl, pH 8.0, 0.2 
mM EGTA, 1 mM DTT, and 0.1 mM PMSF) before flash freezing at -80°C.  
4.2 ACD-crosslinked actin oligomer preparation 
 Monomeric actin was first diluted to 20 µM in reaction buffer (5 mM HEPES, pH 8.0, 0.2 
mM ATP, and 0.1 mM PMSF) and mixed with 10 nM ACDAh and 1 mM MgCl2 to begin the 
crosslinking reaction, which was allowed to proceed for 45 min at 10°C. The reaction was 
terminated by heat inactivation at 42°C for 20 min. To remove uncrosslinked actin, the 
concentration of MgCl2 was brought to a final concentration of 3 mM and the sample was 
incubated at 25°C for 30 min to allow the non-crosslinked actin species for fully polymerize. The 
non-crosslinked actin, now polymerized, was removed by centrifugation at 300,000 g for 30 min 
at 4°C using a TLA-100 rotor in an Optima TL-100 ultracentrifuge (Beckman Coulter). The 
supernatant containing the actin oligomers was supplemented with 1 mM ATP and used in less 




4.3 Actin labeling with pyreneiodoacetamide 
 Pyrene-labeled actin was prepared as previously described (30). 
4.4 Actin polymerization assays  
Gel-filtered Ca2+-ATP G-actin (5% pyrenyl-labeled; 2.5 µM final concentration) was pre-
mixed in black 384-well plates with 20 nM of Ena(ΔL), varying (0-200 nM) concentrations of 
actin oligomers, and with and without 5 µM PFN1 (all concentrations are given as final) in the 
reaction buffer (10 mM MOPS, pH 7.0, 0.2 mM ATP, and 0.5 mM DTT). Then, Ca2+-ATP G-
actin was converted to Mg2+-ATP G-actin by adding 0.066 volumes of switch buffer (150 mM 
MOPS, pH 7.0, 3 mM ATP, 7.5 mM DTT, 4.5 mM EGTA, and 1.5 mM MgCl2) and incubating 
at room temperature for 1 min. Polymerization was initiated by adding 0.33 volumes of initiation 
buffer (30 mM MOPS, pH 7.0, 0.6 mM ATP, 1.5 mM DTT, 150 mM KCl, and 3 mM MgCl2). 
Pyrene fluorescence was monitored at λex = 365 nm and λem = 407 nm using an Infinite M1000 
Pro plate reader (Tecan).  
Assays where oligomers were added at ~15% max polymerization were completed using 
the same method as described for actin polymerization assays. After approximately 200 s and 
960 s for without PFN1 and with PFN1, respectively (~ 15% max polymerization), 0.066 
volumes of varying (0-200 nM) concentrations of actin oligomers were added and pyrene 
fluorescence monitoring was resumed. The oligomers were not pre-mixed with Ena and with and 
without PFN1. 
4.5 Data analysis 
 Inhibition of polymerization by actin oligomers was assessed through the calculation of 
the tangent slope of each pyrene fluorescence trace at 50% (linear intervals of polymerization 
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curves at 40-60% were assessed) of maximum polymerization. The obtained inhibition was fitted 
to a binding isotherm equation using Origin software (OriginLab):  
 ∆!
∆!!"#
=  !!!! !"!"! (!!!! !"!")
!!!∙!∙!
!∙!
               (1) 
where M = Ena(ΔL) concentration, X = concentration of crosslinked actin oligomers, IC50 = the 
oligomer concentration causing 50% inhibition of Ena(ΔL) activity, ΔF = the observed pyrene 
fluorescence change, and ΔFmax = the maximum pyrene fluorescence change. 
 The error bars on the IC50 plots are an indication for the variance in each data set. In each 
plot, three sets of data were combined and the marker indicates the average value at each 
concentration of the three sets. The isotherm binding equation was then fit to these average 







Figure 1: Crosslinked actin oligomers have a twist in subdomain 2 that disrupts the normal 
inter-subunit interface between actin monomers during the formation of an actin filament, 
resulting in its inability to polymerize. The P indicates a phosphate group, as the formation 
of glutamyl phosphate is an intermediate and activation step of the ACD catalysis. Adapted 
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Figure 2: A) Full-length Ena with linker region. B) Ena(ΔL) construct with the linker 
region removed. Numbering represents amino acids. Both constructs have an N-terminal 
MBP and C-terminal His6 tag that were not removed after purification since they did not 




























Figure 3: SDS-PAGE of Ena(ΔL) purification. Ena(ΔL) was purified via metal affinity 













Figure 4: Effects of various Ena(ΔL) concentrations on polymerization of 2.5 µM actin in 










Figure 5: Effects of various oligomer concentrations on polymerization of 2.5 µM actin 
















Figure 6: Isotherm binding plot of various oligomer concentrations on polymerization of 
2.5 µM actin mediated by 20 nM Ena(ΔL) in the absence and presence of PFN1. The 
resulting IC50 values were 3.70 ± 0.95 nM and 3.21 ± 0.53 nM in the absence and presence 







Figure 7: Effects of various oligomer concentrations on polymerization of 2.5 µM actin 






















Figure 8: Effects of various oligomer concentrations on seeds that were generated by 
incubation of 2.5 µM actin in the presence of 20 nM Ena(ΔL). Polymerization was initiated 





















Figure 9: Isotherm binding plot of various oligomer concentrations on seeded 
polymerization of 2.5 µM actin mediated by 20 nM Ena(ΔL) in the absence and presence of 
PFN1. The resulting IC50 values were 5.80 ± 0.69 nM and 2.73 ± 0.45 nM in the absence 






Figure 10: Effects of various oligomer concentrations on seeds that were generated by 
incubation of 2.5 µM actin in the presence of 20 nM Ena(ΔL) and 5 µM PFN1. 
Polymerization was initiated with physiological salt concentrations and oligomers were 
































Figure 11: The proposed mechanism of Ena inhibition by the ACD-crosslinked actin oligomers. 
A) The EVH2 domain of Ena(ΔL) processively binds to a growing barbed end of an actin 
filament and accelerates filament elongation. Additional monomers can get incorporated through 
interactions with the GAB domain and subsequent binding to the filament. B) Once the ACD-
crosslinked actin oligomer binds to multiple GAB domains on Ena(ΔL), additional monomers 
cannot be added to the filament. The addition of the oligomer has turned Ena(ΔL) into a capping 
protein. We believe that oligomer binding to multiple GAB domains simultaneously provides the 
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